Royal Capital Wealth Management LLC Lowers Position in Johnson & Johnson (NYSE:JNJ)

Royal Capital Wealth Management LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,901 shares of the company’s stock after selling 138 shares during the quarter. Johnson & Johnson makes up about 1.0% of Royal Capital Wealth Management LLC’s portfolio, making the stock its 24th biggest holding. Royal Capital Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,301,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Gilbert & Cook Inc. increased its stake in shares of Johnson & Johnson by 3.3% in the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after purchasing an additional 288 shares in the last quarter. 9258 Wealth Management LLC raised its stake in shares of Johnson & Johnson by 2.1% during the 4th quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock worth $3,454,000 after buying an additional 443 shares during the period. Gryphon Financial Partners LLC lifted its position in shares of Johnson & Johnson by 66.3% during the 4th quarter. Gryphon Financial Partners LLC now owns 14,245 shares of the company’s stock valued at $2,244,000 after buying an additional 5,680 shares in the last quarter. Portfolio Design Labs LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at $5,932,000. Finally, Focus Financial Network Inc. ADV acquired a new position in Johnson & Johnson during the fourth quarter worth $14,174,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JNJ. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Sanford C. Bernstein increased their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. TD Securities reduced their price objective on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Finally, Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Trading Down 0.3 %

JNJ opened at $162.80 on Wednesday. The business’s 50-day simple moving average is $161.82 and its 200-day simple moving average is $154.18. The company has a market cap of $391.90 billion, a P/E ratio of 10.15, a PEG ratio of 2.69 and a beta of 0.53. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter in the previous year, the firm earned $2.80 EPS. The company’s revenue was up 4.3% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.05%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.